Testicular cancer · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~8.4 mo | ~34.0 mo | ~10 | ~R 334 331 PFS proxy · indirect | 29 |
Oxaliplatin and Bevacizumab Variant #01 | — | R 19 996 | 14d | — | — | — | — | — |
Gemcitabine, Oxaliplatin, Paclitaxel Variant #01 | — | R 4 782 | 21d | — | — | — | — | — |
Etoposide monotherapy Variant #01 | — | R 2 872 | 28d | — | — | — | — | — |
GemOx Variant #01 | — | R 2 335 | 14d | ~5.0 mo | ~9.0 mo | ~11 | ~R 25 688 PFS proxy · indirect | 5 |
Gemcitabine and Paclitaxel N/A - secondary systemic drug | — | R 263 | 28d | — | ~7.8 mo | — | — | — |
Plicamycin monotherapy Variant #01 Partial | — | — | 30d | — | — | — | — | — |
7 of 7 regimens shown